Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India

References

• Tacconelli E, Carrara E, Savoldi A, et al; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 18;2018:318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Sato T, Cefiderocol: YK, Discovery C. In Vivo Profiles of a Novel Siderophore Cephalosporin. Clin Infect Dis. 2019;69:S538–43. doi:10.1093/cid/ciz826
   PubMed Web of Science ®Google Scholar
• Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother. 2021;76:1379–1391. doi:10.1093/jac/dkab015
   PubMed Web of Science ®Google Scholar
• Syed YY. Cefiderocol: a Review in Serious Gram-Negative Bacterial Infections. Drugs. 2021;81:1559–1571. doi:10.1007/s40265-021-01580-4
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty Ninth Informational Supplement. Wayne, PA: M100-S29. Clinical and Laboratory Standards Institute; 2019.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Thirtieth Informational Supplement. Wayne, PA: M100-S30. Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Morris CP, Bergman Y, Tekle T, Fissel J, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol. 2021;59:e01649–20.
   Web of Science ®Google Scholar
• Matuschek E, Longshaw C, Takemura M, Yamano Y, Kahlmeter G. Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. J Antimicrob Chemother. 2022;1:dkac080.
   Google Scholar
• Kois AK, Nicolau DP, Kuti JL. Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. Curr Opin Infect Dis. 2020;33(6):482–494. doi:10.1097/QCO.0000000000000682
   Web of Science ®Google Scholar
• Veeraraghavan B, Shankar C, Karunasree S, et al. Carbapenem-resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience. Pathog Glob Health. 2017;111:240–246. doi:10.1080/20477724.2017.1340128
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of Cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2019;53:177–184. doi:10.1016/j.ijantimicag.2018.10.007
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Yamano Y, et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017;61:e00093–17. doi:10.1128/AAC.00093-17
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Hackel MA, Tsuji M, et al. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019;53:456–466. doi:10.1016/j.ijantimicag.2018.11.007
   PubMed Web of Science ®Google Scholar
• Naas T, Lina G, Santerre Henriksen A, Longshaw C, Jehl F. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France. JAC Antimicrob Resist. 2021;3:dlab081. doi:10.1093/jacamr/dlab081
   PubMedGoogle Scholar
• Longshaw C, Manissero D, Tsuji M, Echols R, Yamano Y. In vitro activity of the siderophore cephalosporin, Cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe. JAC Antimicrob Resist. 2020;dlaa060. doi:10.1093/jacamr/dlaa060
   Google Scholar
• Candel FJ, Santerre Henriksen A, Longshaw C, Yamano Y, Oliver A. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Clin Microbiol Infect. 2022;28(447):e1–447. doi:10.1016/j.cmi.2021.07.018
   Web of Science ®Google Scholar
• Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2020;64:e01582–20. doi:10.1128/AAC.01582-20
   PubMed Web of Science ®Google Scholar
• Iregui A, Khan Z, Landman D, Quale J. Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City. Microb Drug Resist. 2020;26:722–726. doi:10.1089/mdr.2019.0298
   PubMed Web of Science ®Google Scholar
• Ghebremedhin B, Ahmad-Nejad P. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany. Pathogens. 2021;10:1258. doi:10.3390/pathogens10101258
   Web of Science ®Google Scholar
• Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains. Antimicrob Agents Chemother. 2015;60:729–734. doi:10.1128/AAC.01695-15
   PubMed Web of Science ®Google Scholar
• Bonnin RA, Emeraud C, Jousset AB, Naas T, Dortet L. Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales. Clin Microbiol Infect. 2022;S1198–743. doi:10.1016/j.cmi.2022.04.013
   Web of Science ®Google Scholar
• Ito A, Nishikawa T, Matsumoto S, et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:7396. doi:10.1128/AAC.01405-16
   PubMed Web of Science ®Google Scholar
• Ito A, Nishikawa T, Ota M, et al. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J Antimicrob Chemother. 2018;73:3049–3052. doi:10.1093/jac/dky317
   PubMed Web of Science ®Google Scholar